Novel strategies for treatment-resistant depression

Psychiatric Clinics of North America

Volumn 19, Issue 2, 1996, Pages 387-405

  Hornig Rohan, M ^a   Wolkowitz, O M ^a   Amsterdam, J D ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; DEXAMETHASONE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PINDOLOL; PSYCHOSTIMULANT AGENT; RESERPINE; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE;

DEPRESSION; ELECTROCONVULSIVE THERAPY; HOST RESISTANCE; HUMAN; MEDICAL DECISION MAKING; PHOTOTHERAPY; PRIORITY JOURNAL; PSYCHOSURGERY; PSYCHOTHERAPY; REVIEW; SLEEP DEPRIVATION; TREATMENT PLANNING;

EID: 0030012785     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(05)70294-X     Document Type: Article

References (133)

1. J.D. Amsterdam Use of high dose tranylcypromine in resistant depression J. Amsterdam Refractory Depression 1991 Raven Press New York 123 130
2. J.D. Amsterdam N. Berwish Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy J Clin Psychopharmacol 7 1987 238 242
3. J.D. Amsterdam N. Berwish High dose tranylcypromine treatment in refractory depression Pharmacopsychiatry 22 1989 21 25
4. J.D. Amsterdam D. Brunswick J. Mendels High dose desipramine, plasma drug levels, and clinical response J Clin Psychiatry 40 1979 141 143
5. J.D. Amsterdam D.J. Brunswick J. Mendels The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels Am J Psychiatry 137 1980 653 662
6. J.D. Amsterdam D.J. Brunswick J. Mendels Reliability of commercially available tricyclic antidepressant levels J Clin Psychiatry 41 1980 206 207
7. J.D. Amsterdam G. Maislin L. Potter Fluoxetine efficacy in treatment resistant depression Prog Neuropsychopharmacol Biol Psychiatry 18 1994 243 261
8. J.D. Amsterdam M. Rosenzweig P.D. Mozley Assessment of adrenocortical activity in refractory depression: Steroid suppression with ketoconazole W.A. Nolen J. Zohar S.P. Roose J.D. Amsterdam Refractory Depression: Current Strategies and Future Directions 1994 John Wiley & Sons Chichester 199 210
9. J.D. Amsterdam G. Maislin M. Droba The ACTH stimulation test before and after clinical recovery from depression Psychiatry Res 20 1987 325 336
10. J.D. Amsterdam G. Maislin P.W. Gold The assessment of abnormalities in hormonal responsiveness at multiple levels of the hypothalamic-pituitary-adrenocortical axis in depressive illness Psychoneuroendocrinology 14 1989 43 62
11. J.D. Amsterdam G. Maislin A. Winokur Pituitary and adrenocortical responses to ovine corticotropin-releasing hormone stimulation test Arch Gen Psychiatry 44 1987 775 781
12. APA Task Force on Laboratory Tests in Psychiatry The dexamethasone suppression test: An overview of its current status in psychiatry Am J Psychiatry 144 1987 1253 1262
13. G.W. Arana Intravenous dexamethasone for symptoms of major depressive disorder [letter] Am J Psychiatry 148 1991 1401 1402
14. G.W. Arana R.A. Forbes Dexamethasone for the treatment of depression: A preliminary report J Clin Psychiatry 52 1991 304 306
15. G.W. Arana A.B. Santos M.T. Laraia Dexamethasone for the treatment of depression: A randomized, placebo-controlled, double-blind trial Am J Psychiatry 152 1995 265 267
16. R.B. Aranow J.I. Hudson H.G. Pope Jr Elevated antidepressant plasma levels after addition of fluoxetine Am J Psychiatry 146 1989 911 913
17. F. Artigas V. Perez E. Alvarez Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors Arch Gen Psychiatry 51 1994 248 251
18. D. Bakish Fluoxetine potentiation by buspirone: Three case histories Can J Psychiatry 36 1991 749 750
19. D. Bakish Potentiation of fluoxetine by buspirone and trazodone in refractory depression W.A. Nolen J. Zohar S.P. Roose J.D. Amsterdam Refractory Depression: Current Strategies and Future Directions 1994 John Wiley & Sons Chichester 143 145
20. Bakish D, Hooper CL, West DL, et al: Moclobemide and specific serotonin re-uptake inhibitor combination treatment of resistant anxiety and depressive disorders. Human Psychopharmacology, in press
21. H.T. Ballantine A.J. Bouckoms E.K. Thomas Treatment of psychiatric illness by stereotactic cingulotomy Biol Psychiatry 22 1987 807 819
22. N. Barden J.M.H.M. Reul F. Holsboer Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 18 1995 6 11
23. I.A. Barkai D.L. Dunner H.A. Gross Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder Biol Psychiatry 13 1978 65 72
24. B.M. Baron A.-M. Ogden B.W. Siegel Rapid down regulation of β-adrenoceptors by co-administration of desipramine and fluoxetine Eur J Pharmacol 154 1988 125 134
25. M.D. Beale G.W. Arana Dexamethasone for treatment of major depression in patients with bipolar disorder [letter] Am J Psychiatry 152 1995 959 960
26. C. Berlanga H.A. Ortega-Soto M. Ontiveros Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine Psychiatry Res 44 1992 257 262
27. P. Blier R. Bergeron Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression J Clin Psychopharmacol 15 1995 217 222
28. C. Bolden-Watson E. Richelson Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes Life Sci 52 1993 1023 1029
29. 2 receptor function: Hypothesis for a faster antidepressant action Pharmacol Res 30 1994 1 11
30. A.J. Bouckoms The role of stereotactic cingulotomy in the treatment of intractable depression J. Amsterdam Refractory Depression 1991 Raven Press New York 233 242
31. A.J. Bouckoms L. Mangini Pergolide: An antidepressant adjuvant for mood disorders? Psychopharmacol Bull 29 1993 207 211
32. Brunswick D.J. Amsterdam J.D. Potter L. Relationship between tricyclic antidepressant plasma levels and clinical response in patients treated with desipramine and doxepin Acta Psychiatr Scand 67 1983 371 377
33. D.A. Ciraulo R.I. Shader Fluoxetine drug–drug interactions: I. Antidepressants and antipsychotics J Clin Psychopharmacol 10 1990 48 50
34. C. Clarey L.A. Mandos E. Schweizer Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants J Clin Psychiatry 51 1990 226 231
35. J.O. Cole A.F. Schatzberg C. Sniffin Trazodone in treatment-resistant depression: An open study J Clin Psychopharmacol 1 1981 49S 54S
36. L. Colonna M. Petit J.P. Lepine Bromocriptine in affective disorders J Affect Disord 1 1979 173 177
37. T.B. Cooper G.M. Simpson Concomitant imipramine and methylphenidate administration: A case report Am J Psychiatry 130 1973 721
38. B. Cusack A. Nelson E. Richelson Binding of antidepressants to human brain receptors: Focus on newer generation compounds Psychopharmacology 114 1994 559 565
39. J. Davidson Adding a tricyclic antidepressant to a monoamine oxidase inhibitor J Clin Psychopharmacol 3 1982 216
40. M. Dessauer U. Goetze R. Tölle Periodic sleep deprivation in drug-refractory depression Neuropsychobiology 13 1985 111 116
41. D.P. Doogan V. Caillard Sertraline: A new antidepressant J Clin Psychiatry 49 1988 46 51
42. B.E. Dornseif S.R. Donlop J.H. Potim Effect of dose escalation after low-dose fluoxetine therapy Psychopharmacol Bull 25 1989 71 79
43. M. Fava S.M. Rappe J.A. Pava Relapse in patients on long-term fluoxetine treatment: Response to increased fluoxetine dose J Clin Psychiatry 56 1995 52 55
44. M. Fava J.F. Rosenbaum L. Cohen High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine J Affect Disord 25 1992 229 234
45. M. Fava J.F. Rosenbaum P.J. McGrath Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study Am J Psychiatry 151 1994 1372 1374
46. J. Fawcett H.M. Kravitz J. Zajecka CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression J Clin Psychopharmacol 11 1991 127 132
47. J.P. Feighner J. Herbstein N. Damlouji Combined MAOI, TCA and direct stimulant therapy of treatment resistant depression J Clin Psychiatry 46 1985 206 209
48. R.M. Ferris B.R. Cooper Mechanism of antidepressant activity of bupropion J Clin Psychiatry 11 1993 2 14
49. M. Fink A trial of ECT is essential before a diagnosis of refractory depression is made J. Amsterdam Refractory Depression 1991 Raven Press New York 87 92
50. D.R. Gander Combining the antidepressant drugs BMJ 1 1965 521
51. A.M. Ghadirian F. Englesmann V. Dhar The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment Biol Psychiatry 37 1995 369 375
52. P.W. Gold F.K. Goodwin G.P. Chrousos Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress N Engl J Med 319 1988 413 420
53. P.W. Gold D.L. Loriaux A. Roy Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease: Pathophysiologic and diagnostic implications N Engl J Med 314 1986 1329 1335
54. J.F. Greden R. Gardner D. King Dexamethasone suppression tests in antidepressant treatment of melancholia: The process of normalization and test–retest reproducibility Arch Gen Psychiatry 40 1983 493 500
55. J.B. Greenhouse D.J. Kupfer E. Frank Analysis of time to stabilization in the treatment of depression: Biological and clinical correlates J Affect Disord 13 1987 259 266
56. B.H. Guze L.R. Baxter Jr Refractory depression treated with high doses of a monoamine oxidase inhibitor J Clin Psychiatry 48 1987 31 32
57. Haskovec L. Rysanek K. The action of reserpine in imipramine-resistant depressive patients Psychopharmacologia 11 1967 18 30
58. R.L. Hauger M.R. Irwin R.M. Dupont Treatment-resistant bipolar affective disorder: Phenomenological characteristics, pathophysiological mechanisms, and novel therapies J. Amsterdam Refractory Depression 1991 Raven Press New York 131 154
59. M. Hornig-Rohan J.D. Amsterdam Clinical and biological correlates of treatment-resistant depression: An overview Psychiatr Ann 24 1994 220 227
60. Hornig-Rohan M, Amsterdam JD: Venlafaxine vs. stimulant therapy in patients with dual diagnoses of attention deficit disorder and depression. In Proceedings of the New Clinical Drug Evaluation Unit Annual Meeting, Tampa, May 1995
61. F.M. Jacobsen Possible augmentation of antidepressant response by buspirone J Clin Psychiatry 52 1991 217 220
62. P.G. Janicak J. Lipinski J.M. Davis Parenteral S-adenosyl-methionine (SAMe) in depression: Literature review and preliminary data Psychopharmacol Bull 25 1989 238 242
63. R.T. Joffe D.R. Schuller An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression J Clin Psychiatry 54 1993 269 271
64. S. Kapur J.J. Mann Role of the dopaminergic system in depression Biol Psychiatry 32 1992 1 17
65. S. Kasper S.L.B. Rogers A. Yancey Phototherapy in individuals with and without subsyndromal seasonal affective disorder Arch Gen Psychiatry 46 1989 837 844
66. W. Katon M. Raskind Treatment of depression in the medically ill elderly with methylphenidate Am J Psychiatry 137 1980 963 965
67. S. Kindler Y. Sasson O. Dolberg The role of reserpine augmentation in refractory depression W.A. Nolen J. Zohar S.P. Roose J.D. Amsterdam Refractory Depression: Current Strategies and Future Directions 1994 John Wiley & Sons Chichester 159 162
68. S. Kindler B. Shapira J. Hadjez Factors influencing response to bilateral electroconvulsive therapy in major depression Convuls Ther 7 1991 245 254
69. J. Levine Y. Barak M. Gonzalves A double-blind controlled trial of inositol treatment of depression Am J Psychiatry 152 1995 792 794
70. J. Levine M. Gonzalves I. Babur Inositol 6 gm daily may be effective in depression but not in schizophrenia Human Psychopharmacology 8 1993 49 53
71. A.J. Levitt R.T. Joffe S.H. Kennedy Bright light augmentation in antidepressant nonresponders J Clin Psychiatry 52 1991 336 337
72. L.S. Linet Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine [letter] Am J Psychiatry 146 1989 803 804
73. A.G. Mallinger J.M. Himmelhoch M.E. Thase Plasma tranylcypromine: Relationship to pharmacokinetic variables and clinical antidepressant actions J Clin Psychopharmacol 10 1990 176 183
74. E. Marley K.M. Wozniak Clinical and experimental aspects of interaction between amine oxidase inhibitors and amine re-uptake inhibition Psychol Med 13 1983 735 749
75. P.J. McGrath J.W. Stewart W. Harrison Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor Psychopharmacol Bull 23 1987 169 172
76. H.Y. Meltzer M. Maes H. Elkis The biological basis of refractory depression W.A. Nolen J. Zohar S.P. Roose J.D. Amsterdam Refractory Depression: Current Strategies and Future Directions 1994 John Wiley Chichester 177 198
77. A. Metz R.I. Shader Combination of fluoxetine with pemoline in the treatment of major depressive disorder Int Clin Psychopharmacol 6 1991 93 96
78. B.E.P. Murphy O.M. Wolkowitz The pathophysiologic significance of hypercorticism: Antiglucocorticoid strategies Psychiatr Ann 23 1993 682 690
79. B.E.P. Murphy V. Dhar A.M. Ghadirian Response to steroid suppression in major depression resistant to antidepressant therapy J Clin Psychopharmacol 11 1991 121 126
80. Murphy BEP, Dhar V, Ghadirian AM, et al: Endocrine and psychiatric responses to inhibitors of steroid biosynthesis in patients with antidepressant-resistant major depression. Proceedings of the XXIII Congress of the International Society of Psychoneuroendocrinology, Madison, WI, August 1992
81. E.A. Muth J.T. Haskins J.A. Moyer Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative Biochem Pharmacol 35 1986 4493 4497
82. J.C. Nelson R. Byck Rapid response to lithium in phenelzine nonresponders Br J Psychiatry 141 1982 85 86
83. J.C. Nelson C.M. Mazure M.B. Bowers Jr A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression Arch Gen Psychiatry 48 1991 303 307
84. A.A. Nierenberg K. White What next?: A review of pharmacologic strategies for treatment resistant depression Psychopharmacol Bull 26 1990 429 460
85. A.A. Nierenberg J.O. Cole L. Glass Possible trazodone potentiation of fluoxetine: A case series J Clin Psychiatry 53 1992 83 85
86. A.A. Nierenberg J.F. Feighner R. Rudolph Venlafaxine for treatment-resistant unipolar depression J Clin Psychopharmacol 14 1994 419 423
87. M.S. Nobler H.A. Sackeim Refractory depression and electroconvulsive therapy W.A. Nolen J. Zohar S.P. Roose J.D. Amsterdam Refractory Depression: Current Strategies and Future Directions 1994 John Wiley & Sons Chichester 69 81
88. W.A. Nolen E. Hoencamp P.M.J. Haffmans Classical and selective monoamine oxidase inhibitors in refractory major depression W.A. Nolen J. Zohar S.P. Roose J.D. Amsterdam Refractory Depression: Current Strategies and Future Directions 1994 John Wiley Chichester 59 68
89. W.A. Nolen J.J. van de Putte W.A. Dijken Treatment strategies in depression: II. MAO inhibitors in depression resistant to cyclic antidepressants: Two controlled cross-over studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine Acta Psychiatr Scand 78 1988 676 683
90. A. Novac Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with generalized anxiety disorder J Clin Psychiatry 53 1992 67
91. A.C. Pande M.M. Calarco L.J. Grunhaus Combined MAOI-TCA treatment in refractory depression J. Amsterdam Refractory Depression 1991 Raven Press New York 115 121
92. B.W.M.M. Peeters R. van der Heijden D.G. Gubbels Effects of chronic antidepressant treatment on the hypothalamic-pituitary-adrenal axis of Wistar rats Ann NY Acad Sci 746 1994 449 452
93. R.M. Post Anticonvulsants as adjuncts or alternatives to lithium in refractory bipolar illness J.D. Amsterdam Refractory Depression 1991 Raven Press New York 155 165
94. R.M. Post T.A. Ketter P.J. Pazzaglia Anticonvulsants in refractory mood disorders W.A. Nolen J. Zohar S.P. Roose J.D. Amsterdam Refractory Depression: Current Strategies and Future Directions 1994 John Wiley Chichester 97 114
95. W.Z. Potter H.K. Manji Dopaminergic drugs and systems in refractory depression W.A. Nolen J. Zohar S.P. Roose J.D. Amsterdam Refractory Depression: Current Strategies and Future Directions 1994 John Wiley Chichester 211 227
96. S. Preskorn Antidepressant drug selection: Criteria and options J Clin Psychiatry 55 suppl A 1994 6 22
97. L.H. Price D.S. Charney G.R. Heninger Reserpine augmentation of desipramine in refractory depression: Clinical and neurobiological effects Psychopharmacology 92 1987 431 437
98. F.M. Quitkin The importance of dosage in prescribing antidepressants Br J Psychiatry 147 1985 593 597
99. C.L. Ravaris C. Brinck-Johnsen B. Elliott Clinical use of ketoconazole in hypocortisoluric depressives Biol Psychiatry 35 1994 679
100. C.L. Ravaris A. Nies D. Robinson A multiple–dose, controlled study of phenelzine in depression-anxiety states Arch Gen Psychiatry 33 1976 347 350
101. V.I. Reus Pituitary-adrenal disinhibition as the independent variable in the assessment of behavioral symptoms Biol Psychiatry 17 1982 317 325
102. Ribiero S.C.M. Tandon R. Grunhaus L. The DST as a predictor of outcome in depression: A meta-analysis Am J Psychiatry 150 1993 1618 1629
103. K. Rickels J.P. Feighner W.T. Smith Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression Arch Gen Psychiatry 42 1985 134 141
104. D.S. Robinson High-dose monoamine oxidase-inhibitor therapy JAMA 250 1983 2212
105. D.S. Robinson N.M. Kurtz Monoamine oxidase inhibiting drugs: Pharmacologic and therapeutic issues H.Y. Meltzer Psychopharmacology: The Third Generation of Progress 1987 Raven Press New York 1297 1304
106. J.S. Rosenthal M.J. Kasawan C. Hemlock Fluoxetine enhancement of heterocyclic antidepressants J.D. Amsterdam Refractory Depression 1991 Raven Press New York 105 108
107. N.E. Rosenthal D.A. Sack J.C. Gillin Seasonal affective disorder: A description of the syndrome and preliminary findings with light therapy Arch Gen Psychiatry 41 1984 72 80
108. M.V. Rudorfer W.Z. Potter Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the “newer” versus the “older” drugs Drugs 37 1989 713 718
109. S.L. Satel J.C. Nelson Stimulants in the treatment of depression: A critical overview J Clin Psychiatry 50 1989 241 249
110. A.F. Schatzberg A.J. Rothschild P.J. Langlais A corticosteroid/dopamine hypothesis for psychotic depression and related states J Psychiatr Res 19 1985 57
111. E. Schweizer K. Rickels J.D. Amsterdam What constitutes an adequate antidepressant trial of fluoxetine? J Clin Psychiatry 51 1990 8 11
112. E.R. Sethna A study of refractory cases of depressive illness and their response to combined antidepressant treatment Br J Psychiatry 124 1974 265 272
113. M.T. Shea P.A. Pilkonis E. Beckham Personality disorders and treatment outcome in the NIMH Treatment of Depression Collaborative Research Program Am J Psychiatry 147 1990 711 718
114. B. Shopsin N.S. Kline Monoamine oxidase inhibitors: Potential for drug abuse Biol Psychiatry 11 1976 451 456
115. T. Silverstone Response to bromocriptine distinguishes bipolar from unipolar depressions Lancet 1 1984 903 904
116. G.M. Simpson E. Frederickson R. Palmer Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use Biol Psychiatry 20 1985 684 687
117. S. Stahl 5HT receptors and pharmacotherapy: Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 30 1994 39 43
118. W.S. Stern N. Harto-Truax N. Bauer Efficacy of bupropion in tricyclic-resistant or intolerant patients J Clin Psychiatry 44 1983 138 152
119. F. Sulser Serotonin-norepinephrine receptor interactions in the brain: Implications for the pharmacology and pathophysiology of affective disorders J Clin Psychiatry 48 1987 12 18
120. M.E. Thase The roles of psychosocial factors and psychotherapy in refractory depression: Missing pieces in the puzzle of treatment resistance? W.A. Nolen J. Zohar S.P. Roose Refractory Depression: Current Strategies and Future Directions 1994 John Wiley & Sons Chichester 83 95
121. P. Tyrer Towards rational treatment with monoamine oxidase inhibitors Br J Psychiatry 128 1976 354 360
122. R.H. van den Hoofdakker M.C.M. Gordijn S. Kasper Sleep deprivation in refractory depression W.A. Nolen J. Zohar S.P. Roose J.D. Amsterdam Refractory Depression: Current Strategies and Future Directions 1994 John Wiley & Sons Chichester 129 142
123. L. Warneke Psychostimulants in psychiatry Can J Psychiatry 35 1990 3 10
124. J.B. Weilburg J.F. Rosenbaum J. Biederman Fluoxetine added to non–MAOI antidepressants converts nonresponders to responders: A preliminary report J Clin Psychiatry 50 1989 447 449
125. Weisler R, Risner ME, Ascher J, et al: Use of lamotrigine in the treatment of bipolar disorder. Proceedings of the Annual American Psychiatric Association Meeting, Philadelphia, May 1994
126. R.N. Wharton J.M. Perel P.G. Dayton A potential clinical use for methylphenidate (Ritalin) with tricyclic antidepressants Am J Psychiatry 127 1971 1619 1625
127. K. White G. Simpson Combined MAOI tricyclic antidepressant treatment: A reevaluation J Clin Psychopharmacol 1 1981 264 282
128. O.M. Wolkowitz Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids Psychoneuroendocrinology 19 1992 233 255
129. O.M. Wolkowitz V.I. Reus T. Chan Antiglucocorticoid treatment of depression: A double-blind ketoconazole study In review 1996
130. Wolkowitz OM, Reus VI, Manfredi F, et al: Double-blind dexamethasone treatment of depression. Am J Psychiatry, in press
131. O.M. Wolkowitz V.I. Reus H. Weingartner Cognitive effects of corticosteroids Am J Psychiatry 147 1990 1297 1303
132. S.W. Woods G.E. Tesar G.B. Murray Psychostimulant treatment of depressive disorders secondary to medical illness J Clin Psychiatry 47 1986 12 15
133. J. Zohar Z. Kaplan J.D. Amsterdam Reserpine augmentation in resistant depression: A review J. Amsterdam Refractory Depression 1991 Raven Press New York 219 222